Kazuhiro Usui
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Humidifier lung diagnosed by integrating environmental assessment and inhalation provocation testing: a case with Purpureocillium lilacinum as the most likely causative antigen.
Journal: Respiratory medicine case reports
Published: March 31, 2026
Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer.
Journal: Anticancer research
Published: November 19, 2024
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.
Journal: Japanese journal of clinical oncology
Published: October 28, 2024
Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study.
Journal: Japanese journal of clinical oncology
Published: October 27, 2024
Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study.
Journal: Japanese journal of clinical oncology
Published: October 24, 2024
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.
Journal: Thoracic cancer
Published: September 25, 2024
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 03, 2024
The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).
Journal: JTO clinical and research reports
Published: June 04, 2024
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
Journal: Thoracic cancer
Published: June 28, 2023
Identification of age-dependent features of human bronchi using explainable artificial intelligence.
Identification of age-dependent features of human bronchi using explainable artificial intelligence.
Journal: ERJ open research
Published: June 02, 2023
Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report.
Journal: Case reports in oncology
Published: November 09, 2022
Last Updated: 09/26/2026